Evidence map›Paper›PMID 41335366›Full record

ArticleInternational journal of hematology2026

Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS.

Taku Kikuchi, Shotaro Sugita, Ukyo Kondo, Miyu Watanabe, Chiaki Matsumoto, Moe Nomura-Yogo, Kodai Kunisada, Kota Sato, Tomomi Takei, Mizuki Ogura and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Taku Kikuchi *Department of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan. taku_k_1123@mac.com.ORCID http://orcid.org/0000-0002-3210-7756
Shotaro Sugita *Department of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Ukyo KondoDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Miyu WatanabeDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Chiaki MatsumotoDepartment of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
Moe Nomura-YogoDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Kodai KunisadaDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Kota SatoDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Tomomi TakeiDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Mizuki OguraDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Yu AbeDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Osamu HosoyaDepartment of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.
Nobuhiro TsukadaDepartment of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElranatamab, a bispecific antibody targeting B-cell maturation antigen and CD3, has demonstrated efficacy in relapsed/refractory multiple myeloma (RRMM). However, real-world evidence is limited, and prognostic factors have not been sufficiently evaluated.

methodsWe retrospectively analyzed patients with RRMM receiving elranatamab between June 2024 and July 2025. Responses were assessed using the International Myeloma Working Group criteria. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Prognostic factors were evaluated using univariate log-rank analysis, including R2-ISS at elranatamab initiation (dynamic R2-ISS) and modified MyCARe risk, with positivity defined as any detectable plasma cells in peripheral blood.

resultsThirty-seven patients were evaluated (median age, 67 years; prior lines, 5). Median follow-up was 7.5 (median PFS, 9.7) months. One-year OS was 66.3%. The overall response rate was 67.6%, and 45.9% achieved at least a very good partial response. Extramedullary disease, plasma cells in the peripheral blood, and high-risk cytogenetics were adverse features. A baseline monocyte count < 300/µL, high-risk classification by modified MyCARe, and dynamic R2-ISS stage IV were significantly associated with shorter PFS and OS.

conclusionElranatamab was effective in real-world settings. Baseline monocyte count, modified MyCARe risk, and dynamic R2-ISS may serve as practical prognostic tools.

Indexed as

MonocytesMultiple MyelomaAdultAgedAged, 80 and overFemaleHumansLeukocyte CountMaleMiddle AgedPrognosisRecurrenceRetrospective StudiesTreatment OutcomeElranatamabMonocyteMultiple myelomaMyCAReR2-ISS

Identifiers

PMID41335366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.